Tracks outcomes and side effects in people with sarcoma or gastrointestinal cancer
Observes outcomes and side effects in adults with sarcoma or gastrointestinal cancer receiving standard treatment.
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Registry title
- Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 17 Mar 2023
- Expected to end
- 1 Jan 2036
- Type of study
- Observational
- Treatments tested
- Survey
- Toxicity Assessments
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a cancer of the digestive system or a sarcoma (bone or soft tissue) who are being treated with standard care, including radiotherapy. It follows disease outcomes and side effects.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Proof of a digestive system (gastrointestinal) cancer or sarcoma, shown by tissue tests, cell tests, or scans.
Main reasons for not taking part
- Cannot or does not want to give informed consent
- Does not expect to be available or willing to come to follow-up visits after treatment
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below
- Subject is willing and able to provide written informed consent to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer
- Age ≥ 18 years at the time of consent
- Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal malignancy or sarcoma
- Females with childbearing potential and male subjects with fathering potential are allowed to participate in this study
Who cannot take part
- All subjects meeting any exclusion criteria at baseline will be excluded from study participation
- Inability or unwillingness to provide informed consent
- Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment
Where in United States
- University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, United StatesContact: Victoria XuTaking people
About the trial
What the trial wants to find out
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.
Read full original descriptionShow less
Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.
The group in the trial
- Single Arm
Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
Treatment: Survey and Toxicity Assessments
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
- Plain-language title
- Tracks outcomes and side effects in people with sarcoma or gastrointestinal cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 March 2026